Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal study without human data
PubMed 39426381 · doi:10.1016/j.stem.2024.09.013
What was done
Researchers induced Yamanaka factors (YFs) in mouse brains using spatiotemporally controlled methods across two paradigms: during embryonic brain development and during adulthood in the dorsal hippocampus of a 5xFAD Alzheimer's disease mouse model. They assessed cell identity, neural progenitor expansion, cortical neuron and glial cell counts, behavioral outcomes (motor and social behavior), and Alzheimer's disease pathology including cognitive decline and molecular signatures.
What was found
The abstract reports no numerical values, effect sizes, or confidence intervals. Qualitatively, transient low-level embryonic YF induction was tolerated and resulted in progenitor expansion, an increased number of upper cortical neurons and glia, and enhanced adult motor and social behaviors. In adult 5xFAD mice, controlled hippocampal YF expression was tolerated by principal neurons and prevented the development of several Alzheimer's disease hallmarks, including cognitive decline and altered molecular signatures.
Why it matters
This study demonstrates that controlled, transient in vivo cellular reprogramming can safely expand specific neural cell populations during neurogenesis and counteract neurodegenerative features in a mouse model of Alzheimer's disease.
Limits
The findings are derived entirely from mouse models and cannot be directly generalized to human physiology. The abstract provides no sample sizes, exact quantitative measures, effect sizes, or statistical metrics, and potential long-term safety risks such as tumorigenesis or off-target epigenetic disruption were not detailed in the abstract.
Cited by
- partial Reversing the biological age of the brain in mouse models of Alzheimer's disease causes the disease and dementia symptoms to resolve.